The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Teriparatide to Denosumab Switch Helpful in Osteoporosis

Teriparatide to Denosumab Switch Helpful in Osteoporosis

July 16, 2015 • By David Douglas

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research.

You Might Also Like
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
  • High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost
  • Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA

In a July 3 online paper in The Lancet, Dr. Benjamin Z. Leder, of Massachusetts General Hospital, Boston, and colleagues noted that many osteoporosis patients are treated sequentially with two or more therapies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although sequential anabolic and bisphosphonate have been well studied, this is not the case for sequential use of denosumab and teriparatide.

The researchers conducted an extension study of 83 women who had originally been randomly assigned to 24 months of teriparatide (20 mg daily), denosumab (60 mg every 6 months), or both drugs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The teriparatide participants switched to denosumab, the denosumab participants to teriparatide, and those receiving both drugs switched to denosumab alone. In all, 69 completed this 24-month extension trial.

After 48 months, mean spine bone mineral density increased by 18.3% in women in the teriparatide to denosumab group, 14.0% in the denosumab to teriparatide group, and 16.0% in the combination to denosumab group.

These differences were not significant across groups. However, total hip bone mineral density increased more in the teriparatide to denosumab group (6.6%) than in the denosumab to teriparatide group (2.8%), but had the greatest increase in the combination to denosumab group (8.6%). Femoral neck bone mineral density increased in a similar manner.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In addition, radius bone mineral density was unchanged in the teriparatide to denosumab group but decreased by 1.8% in the denosumab to teriparatide group, and increased by 2.8% in the combination to denosumab group.

The investigators concluded that “In postmenopausal osteoporotic women switching from teriparatide to denosumab, bone mineral density continued to increase, whereas switching from denosumab to teriparatide results in progressive or transient bone loss.”

Commenting on the findings by email, co-author of an accompanying editorial, Dr. Tilman D. Rachner, told Reuters Health, “This is the first trial to show beneficial effects on bone mineral density when using a sequential therapy of teriparatide followed by denosumab.”

“Furthermore,” added Dr. Rachner of Dresden Technical University Medical Center, Germany, “it highlights the importance of choosing the right order when combining different approaches for the treatment of osteoporosis to achieve the best results.”

Dr. Leder did not respond to requests for comments.

Amgen, Eli Lilly, and the National Institutes of Health funded this research. Two coauthors reported relationships with companies, including Amgen and Eli Lilly.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates Tagged With: Amgen, bone loss, bone mineral density (BMD), denosumab, National Institutes of Health (NIH), Osteoporosis, osteoporosis treatments, teriparatide, teriparatide treatment for osteoporosis

You Might Also Like:
  • Denosumab Boosts BMD after Teriparatide Treatment for Osteoporosis
  • High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost
  • Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA
  • Denosumab Does Not Stimulate Early Bone Formation

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.